Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Company Overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for immune-mediated dermatologic and inflammatory diseases. The company’s pipeline comprises both topical and oral drug candidates designed to address significant unmet medical needs in conditions such as actinic keratosis, atopic dermatitis, and alopecia areata. Aclaris employs a precision medicine approach, leveraging its immuno-dermatology platform to advance targeted therapies through clinical development.

The company’s lead program, A-101, is a topical formulation to treat actinic keratosis, a precancerous skin condition. A-101 combines a proprietary gel formulation with synthetic hypericin, aiming to improve lesion clearance with minimal application steps. In addition to A-101, Aclaris is developing a suite of janus kinase (JAK) inhibitors, including ATI-1777 and ATI-1779, formulated for topical use in inflammatory skin disorders, as well as ATI-450, an oral small molecule inhibitor targeting inflammatory pathways for systemic autoimmune diseases.

Founded in 2015 and headquartered in Wayne, Pennsylvania, Aclaris operates research and development facilities in the United States and maintains collaborations in Europe and Asia to support global clinical trials. The company’s multidisciplinary team combines expertise in dermatology, immunology, chemistry, and clinical development to advance its product candidates through regulatory milestones and toward potential commercialization.

Aclaris is led by a management team with deep industry experience, including a seasoned executive board and scientific advisory committee. The leadership team’s collective background spans major pharmaceutical and biotechnology firms, bringing a track record of successful drug development, regulatory approvals, and strategic partnerships. With multiple ongoing clinical studies, Aclaris Therapeutics aims to become a leader in treating immune-mediated dermatologic diseases by delivering innovative therapies that improve patient outcomes.

Key Stats

• Today's Range: $1.44 to $1.50
• 50-Day Range: $1.18 to $1.63
• 52-Week Range: $1.05 to $5.17
• Volume: 567,998 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $158.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.71
• Consensus Rating: Buy

Aclaris Therapeutics Stock Analysis - MarketRank™

Aclaris Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 506th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aclaris Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.82) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aclaris Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aclaris Therapeutics is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aclaris Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.78% of the float of Aclaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aclaris Therapeutics has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Aclaris Therapeutics has recently increased by 2.98%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclaris Therapeutics does not currently pay a dividend.

Dividend Growth

Aclaris Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.78% of the float of Aclaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aclaris Therapeutics has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Aclaris Therapeutics has recently increased by 2.98%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

Aclaris Therapeutics has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.

Search Interest

9 people have searched for ACRS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

Percentage Held by Institutions

98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACRS Stock Analysis - Frequently Asked Questions

How have ACRS shares performed this year?

Aclaris Therapeutics' stock was trading at $2.48 at the beginning of 2025. Since then, ACRS shares have decreased by 41.1% and is now trading at $1.46.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its earnings results on Tuesday, May, 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 732.42% and a negative trailing twelve-month return on equity of 30.73%.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACRS
• CIK: 1557746
• Web: www.aclaristx.com
• Phone: (484) 324-7933
• Fax: 484-320-2344
• Employees: 100
• Year Founded: 2012

Price Target and Rating

• Average Stock Price Target: $9.71
• High Stock Price Target: $16.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +565.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$132.07 million
• Net Margins: -732.42%
• Pretax Margin: -732.42%
• Return on Equity: -30.73%
• Return on Assets: -22.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.06
• Quick Ratio: 5.06

Sales & Book Value

• Annual Sales: $18.72 million
• Price / Sales: 8.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.44 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 108,280,000
• Free Float: 101,351,000
• Market Cap: $158.09 million
• Optionable: Optionable
• Beta: 0.38